Physician profile
Katherine M Devries
NPI 1689875346
$2,329.63
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.25 · 2020: $363 · 2021: $547 · 2022: $311 · 2023: $461 · 2024: $408 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.59 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.99 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $377.40 | 2020-2025 | Farxiga, Fasenra |
| Abbvie INC. | $358.33 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $267.53 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $153.08 | 2020-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.96 | 2020-2025 | Jardiance, Tradjenta |
| Amgen INC. | $79.86 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $68.17 | 2020-2025 | |
| Amarin Pharma, INC. | $60.93 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.98 | 2021-2022 | |
| Esperion Therapeutics, INC. | $55.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $43.58 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $39.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.65 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.43 | 2021 | |
| Eisai INC. | $18.04 | 2019 | |
| Currax Pharmaceuticals LLC | $15.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.86 | 2024 | |
| Dexcom, INC. | $13.34 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.